Exhibit 99.2

Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, Chembio’s ability to develop, manufacture, market and finance new products and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Other factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission. © 2018 Chembio. All Rights Reserved. Page 2

Our VisionTo reduce the incidence of disease globallyOur MissionTo develop and commercialize rapid, easy-to-use, and reliable point-of-care tests that improve diagnosis and monitoring of disease © 2018 Chembio. All Rights Reserved. Page 3

© 2018 Chembio. All Rights Reserved. | # Patented DPP® Technology Platform 99.8%Sensitivity1100% Specificity1 Offers uniqueness and broad global market application 1Based on fingerstick whole blood samples: DPP HIV 1/2 Assay Easy to useFingerstick blood / oral fluidResults in 10-20 minutesHighly sensitive and specificMultiplexing capabilitiesQuantitative Results © 2018 Chembio. All Rights Reserved. Page 4

EXPANDING…Our core sexually transmitted disease (STD) businessBUILDING…A broad tropical and fever disease portfolioLEVERAGING…Our DPP® technology and scientific expertise via collaborationsPREPARING…For additional growth with enhanced manufacturing capability Strategic Focus Executing on our key building blocks © 2018 Chembio. All Rights Reserved. Page 5

Sexually Transmitted Disease Market HIV and Syphilis affect ~50 million globally IMPORTANT GEOGRAPHIESUnited States: FDA approved, CLIA WaivedAfrica: WHO prequalifiedEurope: CE markedBrazil: ANVISA approvedMexico: COFEPRIS approvedMalaysia: MDA approved © 2018 Chembio. All Rights Reserved. Page 7

KEY ADVANTAGESSmall sample size2.5 – 15μL fingerstick blood sample Fast results15-20 minute test timeReliable performanceSensitive and SpecificMultiplexing capabilitiesDPP® HIV-SyphilisDPP® Syphilis Screen & Confirm SURE CHECK® HIV 1/2 Test STAT-PAK® HIV 1/2 Test SURE CHECK® HIV Self Test DPP® HIV-Syphilis Test (International) DPP® SyphilisScreen & Confirm Test © 2018 Chembio. All Rights Reserved. Page 8 Sexually Transmitted Disease Products Multiple products serving unique customer requirements

Global community committed to eliminating mother-to-child transmission Addressing HIV-Syphilis Co-infection United StatesSubmitted U.S. FDA application Q1 2018Expect response by Q3 2018International Regulatory ApprovalsANVISA approved (Brazil)COFEPRIS approved (Mexico)USAID approvedCE markedOther © 2018 Chembio. All Rights Reserved. Page 9 DPP® HIV-Syphilis Test

Building Tropical & Fever Disease Portfolio DPP® Malaria DPP® Dengue DPP® Zika DPP® Chikungunya DPP® Ebola DPP® Typhoid DPP® Fever Panel(Africa) DPP® Malaria-Ebola DPP® Dengue-Zika-Chikungunya DPP® Fever Panel(Asia) Single Tests Multiplex Tests Key advantages include sensitivity, specificity and multiplexing © 2018 Chembio. All Rights Reserved. Page 10

Opportunities in Established MarketsMalaria: 216M annual infectionsDengue: 390M annual infectionsEmerging Markets ZikaChikungunyaEbolaLassaMarburgLeptospirosisBurkholderiaRickettsia Tropical and Fever Disease Market Established markets and channels present significant opportunity © 2018 Chembio. All Rights Reserved. Page 11

Tropical and Fever Disease R&D funding from World-Leading Organizations: $7.3MM (’15-’17) DPP® Malaria DPP® Dengue DPP® Zika DPP® Dengue/Zika/Chikungunya DPP® Fever Panel - Africa DPP® Fever Panel - Asia DPP® Ebola DPP® Malaria/Ebola © 2018 Chembio. All Rights Reserved. Page 12

Technology Collaborations Why are global leaders choosing Chembio to solve their challenges? © 2018 Chembio. All Rights Reserved. Page 13 Deep scientific expertise with a proven technology platformSensitive and specificMultiplexing capabilitiesQuantitative resultsSuccessful track record developing DPP® tests with diverse collaboratorsGlobal commercial companiesGovernmentsNon-governmental organizationsExtensive experience achieving key regulatory approvalsU.S. FDA, WHO PQ, CE mark, ANVISA, COFEPRIS

Technology Collaborations Ongoing collaborations provide significant growth potential DPP® Concussion DPP® Bovine Tuberculosis DPP® Cancer (specific form) DPP® “Undisclosed Biomarker” Point-of-care infectious disease portfolio Perseus Science Group LLC Undisclosed Partner © 2018 Chembio. All Rights Reserved. Page 14 DPP® Hepatitis C Virus

Technology Collaborations What opportunities do our technology collaborations provide? © 2018 Chembio. All Rights Reserved. Page 15 Expansion into new marketsCancer DiagnosticsConcussion / Traumatic Brain InjuryVeterinaryBroadening application from POC diagnostics to companion diagnosticsDrugsVaccinesCost-effective development funded by collaborators Note: all technology collaboration projects are under development

Preparing For Additional Growth Product, People, Process Expanding the product portfolio (STD, Tropical & Fever, Collaborations)Strengthening the talent (Leadership, Board, Organization)Expanding manufacturing capacity (U.S. and Malaysia) © 2018 Chembio. All Rights Reserved. Page 16

© 2018 Chembio. All Rights Reserved. | # Revenue (millions) As of 6/30/2018$9.5M cash and equivalents; $16.9M net working capital Q3 2016 Q3 2017 Q4 2016 Q4 2017 Q1 2017 Q1 2018 Q2 2017 Q2 2018 Financial Highlights Revenue Growth 63% LTM: $18.4M (Q2 ’17) to $30.0M (Q2 ’18) © 2018 Chembio. All Rights Reserved. Page 17 LTM: Last twelve months ended Q2’17 vs. LTM Q2’18

2018 Milestones, Goals and Next Steps Complete DPP® Malaria Assay development  file registrationsComplete DPP® biomarker (AstraZeneca) development  file registrationsSubmit DPP® Zika 510(k) with U.S. FDA  launch in the U.S. marketFile DPP® Dengue registrations  launch in APAC and LATAM marketsComplete DPP® Cancer development  file registrations Driving new revenues © 2018 Chembio. All Rights Reserved. Page 18

Investment Highlights Investment Highlights Superior DPP® technology platform with broad applicationGrowing pipeline of products and markets Nimble global organization prepared to scale operationally © 2018 Chembio. All Rights Reserved. Page 19